Back to Search Start Over

Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial

Authors :
Sara A. Harper
Robert T. Mankowski
Rakesh P. Patel
Christiaan Leeuwenburgh
Marcas M. Bamman
Youfeng Yang
Thomas W. Buford
Stephen D. Anton
John Bassler
Sujitha Peramsetty
Karina C. Ricart
Lisa M. Roberts
Byron C. Jaeger
Devin Drummer
Source :
Exp Gerontol
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Purpose To evaluate the safety and feasibility of combining exercise (EX) and resveratrol to treat older adults with physical function limitations. Methods Three-arm, two-site pilot randomized, controlled trial (RCT) for community-dwelling adults (N = 60), 71.8 ± 6.3 years of age with functional limitations. Participants were randomized to receive either 12 weeks of (1) EX + placebo [EX0], (2) EX + 500 mg/day resveratrol [EX500], or (3) EX + 1000 mg/day resveratrol [EX1000]. EX consisted of two sessions a week for 12 weeks of center-based walking and whole-body resistance training. Safety was assessed through adverse events and feasibility through exercise session and supplement (placebo, or resveratrol) protocol adherence. Outcome measures included a battery of indices of physical function as well as skeletal muscle mitchondrial function. Data were adjusted for age and gender using the Intent-To-Treat approach. Results Adverse event frequency and type were similar between groups (n = 8 EX0, n = 12 EX500, and n = 7 EX1000). Overall, 85% of participants met the supplement adherence via pill counts while 82% met the exercise session adherence. Adjusted within group mean differences (95% confidence interval) from week 0 to 12 for gait speed ranged from −0.04 (EX0: −0.1, 0.03) m/s to 0.04 (EX1000: −0.02, 0.11) and the six-minute walk test mean differences were 9.45 (EX0: −9.02, 27.7), 22.9 (EX500: 4.18, 41.6), and 33.1 (EX1000: 13.8, 52.4) meters. Unadjusted mean differences for citrate synthase were −0.80 (EX0: −15.45, 13.84), −1.38 (EX500: −12.16, 9.39), and 7.75 (EX1000: −4.68, 20.18) mU/mg. COX activity mean within group changes ranged from −0.05 (EX0) to 0.06 (EX500) k/s/mg. Additional outcomes are detailed in the text. Conclusion The pilot RCT indicated that combined EX + resveratrol was safe and feasible for older adults with functional limitations and may improve skeletal muscle mitochondrial function and mobility-related indices of physical function. A larger trial appears warranted and is needed to formally test these hypotheses.

Details

ISSN :
05315565
Volume :
143
Database :
OpenAIRE
Journal :
Experimental Gerontology
Accession number :
edsair.doi.dedup.....8bad29f269f1b16ba618e540718b5404
Full Text :
https://doi.org/10.1016/j.exger.2020.111111